April 28, 2014 / 11:41 AM / 3 years ago

Forest Labs to buy Furiex Pharma for up to $1.46 bln

1 Min Read

April 28 (Reuters) - Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion including milestone payments to access Furiex's treatment for irritable bowel syndrome.

Forest will pay about $95 per share in cash to Furiex shareholders and up to $30 per share in a contingent value right, payable on marketing approval for Furiex's lead drug, eluxadoline.

Forest, which itself is being acquired by Actavis Plc , said Actavis supported the deal announced on Monday.

Forest said it would sell Furiex's royalties on diabetes drug alogliptin and premature ejaculation treatment Priligy to New York-based Royalty Pharma for about $415 million upon successful completion of its acquisition of Furiex. (Reporting by Esha Dey in Bangalore; Editing by Don Sebastian)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below